The Impact of COVID-19 on Specialty Physician Practices is Far from Over, Leaving Pharmaceutical Companies to Assess Whether Traditional Promotional Efforts Will Ever Revert to the Pre-COVID Era

US Hematologists Express High Unmet Need in Treatments for Warm Autoimmune Hemolytic Anemia and Cold Agglutinin Disease

With few treatment options for patients, hematologists look to pipeline agents such as Johnson & Johnson’s nipocalimab and Novartis’ ianalumab to improve patient outcomes, according

Emerging Gene Therapies Signal Transformative Shift in Retinal Disorder Treatment, According to Spherix Global Insights

US retinal specialists identify 4D Molecular Therapeutics’ 4D-150, Adverum Biotechnologies’ Ixo-vec, and Johnson & Johnson’s JNJ-1887 as most likely pipeline candidates for prescription if approved.

Evaluating the Efficacy and Perception of HS Treatment Options

Spherix Global Insights recently delved into the efficacy, patient quality of life, and symptom management of adalimumab vs secukinumab. Managing hidradenitis suppurativa (HS) effectively remains

Docs embrace Takeda’s Eohilia, creating competition for Sanofi, Regeneron’s blockbuster Dupixent

Takeda’s resurrection of the once-rejected Eohilia appears to be paying off, with a survey of physicians finding the launch is in line with the rollout of Dupixent

Takeda’s Eohilia Sees Strong Early Adoption and Growth Potential in Eosinophilic Esophagitis, According to Spherix Global Insights

Impacts of Eohilia’s short-term 12-week label are still unfolding, but prescribers express interest in continuing consecutive treatment courses. EXTON, PA., July 18, 2024 – In

Discrepancies Discovered in the Treatment of People with Refractory Epilepsy by Epileptologists vs General Neurologists

Epileptologists and general neurologists have different approaches to treating people with refractory epilepsy, according to the Market Dynamix: Adult Refractory Epilepsy (US) study conducted by

Experience
genuine
commercial clinical regulatory commercial clinical regulatory commercial clinical regulatory
transformation

Products

Services

Innovtive Technology

End-to-End Services

Benefit Headline

Benefit Headline

Amanda Samples

Title, Company

US Hematologists Express High Unmet Need in Treatments for Warm Autoimmune Hemolytic Anemia and Cold Agglutinin Disease

Emerging Gene Therapies Signal Transformative Shift in Retinal Disorder Treatment, According to Spherix Global Insights

Evaluating the Efficacy and Perception of HS Treatment Options

Docs embrace Takeda’s Eohilia, creating competition for Sanofi, Regeneron’s blockbuster Dupixent

Takeda’s Eohilia Sees Strong Early Adoption and Growth Potential in Eosinophilic Esophagitis, According to Spherix Global Insights

Discrepancies Discovered in the Treatment of People with Refractory Epilepsy by Epileptologists vs General Neurologists

1 (800) 000 0000

info@bridgeview.com

Footer Nav A

Home

Technology

Services

About Us

Footer Nav B

Resources

Terms of Service

Contact

Newsletter

Site Map

©2024 BridgeView Life Sciences

Spherix is excited to announce our expansion into an additional, rapidly evolving specialty market:

HEMATOLOGY

Throughout 2024, we will be publishing over
10 groundbreaking studies covering a wide range of indications within classical hematology.

Experiencegenuine commercial clinical regulatory commercial clinical regulatory commercial clinical regulatory transformation

Innovtive Technology

End-to-End Services

Benefit Headline

Benefit Headline

Amanda Samples

Title, Company

1 (800) 000 0000

info@bridgeview.com

Footer Nav A

Home

Technology

Services

About Us

Footer Nav B

Resources

Terms of Service

Contact

Newsletter

Site Map

©2024 BridgeView Life Sciences

Spherix is excited to announce our expansion into an additional, rapidly evolving specialty market:

HEMATOLOGY

Throughout 2024, we will be publishing over 10 groundbreaking studies covering a wide range of indications within classical hematology.

Experience
genuine
commercial clinical regulatory commercial clinical regulatory commercial clinical regulatory
transformation

Throughout 2024, we will be publishing over
10 groundbreaking studies covering a wide range of indications within classical hematology.